Abstract
We examined the relationship between weight changes after preoperative glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment and weight changes from the start of medical weight management (MWM) until 12months after bariatric surgery in patients with type 2 diabetes in a retrospective cohort study. A total of 45 patients (64.4% women, median [interquartile range] age 49 [45-60] years) were included. The median (interquartile range) weight loss from start of MWM until 12months post-surgery was 17.9% (13.0%-29.3%). GLP-1RA treatment during MWM resulted in 5.0% (1.9%-7.7%) weight loss. Weight loss during GLP-1RA treatment predicted weight loss from the start of MWM until 12months post-surgery, but not postoperative weight loss after adjustment. The proportion of weight loss from start of MWM to 12months post-surgery attributed to GLP-1RA treatment was negatively associated with that attributed to surgery, after adjustment. In conclusion, weight change after GLP-1RA treatment predicted the weight loss achieved by a combination of MWM and bariatric surgery, but not weight loss induced by surgery only. Failure to lose weight after GLP-1RA treatment should not be considered a barrier to undergoing bariatric surgery.
| Original language | English |
|---|---|
| Journal | Diabetes, Obesity and Metabolism |
| Early online date | 20 Oct 2017 |
| DOIs | |
| Publication status | Published - 22 Nov 2017 |
Keywords
- Bariatric surgery
- Glucagon-like peptide-1 receptor agonist
- Laparoscopic adjustable gastric band
- Laparoscopic sleeve gastrectomy
- Obesity
- Roux-en-Y gastric bypass
- Type 2 diabetes mellitus
- Weight loss
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Access to Document
- Tang_et_al_Preoperative_weight_loss_with_GLP-1_Supplementary_Diabetes_Obesity_and_Metabolism_2017
Checked for eligibility: 10/01/2018 Supplementary Material This is the peer reviewed version of the following article: Tang T, Abbott S, CW le Roux, et al. Preoperative weight loss with glucagon-like peptide-1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis. Diabetes Obes Metab. 2017;1–4., which has been published in final form at https://doi.org/10.1111/dom.13131. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
- Tang_et_al_Preoperative_weight_loss_with_GLP-1_Diabetes_Obesity_and_Metabolism_2017
Checked for eligibility: 10/01/2018 This is the peer reviewed version of the following article: Tang T, Abbott S, CW le Roux, et al. Preoperative weight loss with glucagon-like peptide-1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis. Diabetes Obes Metab. 2017;1–4., which has been published in final form at https://doi.org/10.1111/dom.13131. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.